A research team has, for the first time in the world, revealed the identity and differentiation process of human cervical ...

Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced dosing of the first patient in its ...

A joint research team from DGIST, Kyungpook National University Chilgok Hospital, and Dongguk University has revealed the identity of cervical stem cells for the first time in the world - The research ...

Researcher suggests compounds secreted by high-risk MSCs that are detectable in the bloodstream could act as biomarkers for ...

Researchers at the University of Pittsburgh have identified a novel trigger of a deadly form of ovarian cancer: a subset of ...

The Food and Drug Administration (FDA) has granted Fast Track designation to STM-01 for the treatment of heart failure with preserved ejection fraction ...

Researchers at the University of Pittsburgh have identified a novel trigger for a deadly form of ovarian cancer: a subset of ...

Scientists have uncovered a hidden driver of ovarian cancer—high-risk mesenchymal stem cells lurking in the fallopian tubes.

A single molecular switch is essential for blood stem cells to enter an activated, regenerative state in which they produce new blood cells, according to a preclinical study led by Weill Cornell ...

Secretome Therapeutics is developing therapies derived from neonatal cardiac progenitor cells (nCPCs) to address life-threatening cardiovascular diseases and conditions driven by inflammation.